CALLIDITAS THERAPEUTICS-ADR (CALT)

US13124Q1067 - ADR

19.5006  +0.05 (+0.26%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
229.347M
26,141.08%		802.879M
250.07%		1.207B
50.32%		1.999B
65.63%
EBITDA
YoY % growth
N/AN/AN/A325.69M
EBIT
YoY % growth
-524.605M
-37.26%		-414.81M
20.93%		-373.055M
10.07%		354.66M
195.07%
Operating Margin
-228.74%-51.67%-30.91%17.74%
EPS
YoY % growth
N/AN/A-17.368.07
146.48%		N/AN/AN/A

All data in SEK

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-2.55
63.40%
Revenue
Q2Q % growth		397.58M
107.77%
EBITDA
Q2Q % growth		-67.637M
EBIT
Q2Q % growth		-69.783M
61.25%

All data in SEK

Recent Earnings VS Estimates Surprises (SEK)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.68
-385.71%		-3.562.8880.89%
Q3 2023
Q2Q % growth		 -6.28
-1,747.06%		-0.58-5.70-979.13%
Q2 2023
Q2Q % growth		 -3.42
52.76%		-4.441.0222.90%
Q1 2023
Q2Q % growth		 -6.98 -3.50-3.48-99.31%
Recent Revenue VS Estimates Surprises (SEK)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 451.561M
5.25%		364.28M87.281M23.96%
Q3 2023
Q2Q % growth		 294.592M
13.28%		376.01M-81.418M-21.65%
Q2 2023
Q2Q % growth		 269.384M
320.60%		286.08M-16.696M-5.84%
Q1 2023
Q2Q % growth		 191.352M
284.75%		269M-77.648M-28.87%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-472.3% -163.59% -53.42% -61.84%
Revenue-5.23% -26.51% -12.78% -21.97%